Physician Investigator (Cl) Neurology, Mass General Research Institute

Assistant Professor of Neurology Harvard Medical School

Assistant Neurologist Neurology, Massachusetts General Hospital

MD University of Rochester School of Medicine and Dentistry 2007

MPH Harvard T.H. Chan School of Public Health 2021

MPH TH Chan Harvard School of Public Health 2021

MD University of Rochester School of Medicine 2007

cancer immunotherapy; electrodiagnostic medicine; lambert-eaton myasthenic syndrome; myasthenia gravis; neurological complications of cancer; neuromuscular diseases

Dr. Amanda Guidon is a neuromuscular neurologist at the Massachusetts General Hospital and an Assistant Professor of Neurology at Harvard Medical School.  She received her medical degree from the University of Rochester and completed her Internship in Medicine (2008), and Residency in Neurology (2011) as well as Fellowship in Neuromuscular Medicine (2011-2013) at Duke University Medical Center.  She completed a Masters of Public Health at the TH Chan School of Public Health at Harvard in 2021. She received a MGNet Career Development Award and was selected to be an NIH Rare Disease Scholar (2020-2021). Dr. Guidon is board certified in Neurology, Neuromuscular Medicine and Electrodiagnostic Medicine. 

Dr. Guidon's clinical practice is dedicated to patients with neuromuscular disorders, particularly myasthenia gravis.  As part of this work, she directs the Myasthenia Gravis Program at MGH and has held leadership positions regionally and nationally in MG, including serving as current chair of the medical and scientific advisory board of the Myasthenia Gravis Foundation of America (MGFA) in New England. Her care was recognized by the MGFA's physician of the year award in 2020.  She has been program director of the Mass General Brigham Neuromuscular Medicine Fellowship since 2018.  Dr. Guidon's research in outcomes, telemedicine and remote monitoring in MG has been funded by the MGFA, MG Net Rare Disease Network and NINDS.  She is involved in designing and conducting clinical trials in MG.  Dr. Guidon has an additional clinical and research focus in neurologic immune related adverse events (irAEs) of immunotherapy for cancer and she leads the Neuro irAE program at MGH.